KR101733901B1 - 신규한 퀴놀론 유도체 - Google Patents
신규한 퀴놀론 유도체 Download PDFInfo
- Publication number
- KR101733901B1 KR101733901B1 KR1020157016080A KR20157016080A KR101733901B1 KR 101733901 B1 KR101733901 B1 KR 101733901B1 KR 1020157016080 A KR1020157016080 A KR 1020157016080A KR 20157016080 A KR20157016080 A KR 20157016080A KR 101733901 B1 KR101733901 B1 KR 101733901B1
- Authority
- KR
- South Korea
- Prior art keywords
- oxo
- hydroxy
- carboxamide
- alkyl
- dihydroquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*C(**1I***)=C(*)C(NC)=C1C(N*(C)(C=S)C(O)=O)=O Chemical compound C*C(**1I***)=C(*)C(NC)=C1C(N*(C)(C=S)C(O)=O)=O 0.000 description 3
- VIYYDKAHJSAMGJ-UHFFFAOYSA-N C=CCON(c(c(C(O)=C1C(NCC(O)=O)=O)c2)ccc2-c2ccccc2)C1=O Chemical compound C=CCON(c(c(C(O)=C1C(NCC(O)=O)=O)c2)ccc2-c2ccccc2)C1=O VIYYDKAHJSAMGJ-UHFFFAOYSA-N 0.000 description 1
- KZUJYARPHJCVRN-UHFFFAOYSA-N C=CCON(c1cc(Cl)ccc1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound C=CCON(c1cc(Cl)ccc1C(O)=C1C(NCC(O)=O)=O)C1=O KZUJYARPHJCVRN-UHFFFAOYSA-N 0.000 description 1
- APYIJHRTLIKJFB-UHFFFAOYSA-N CC#CCON(c1ccccc1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CC#CCON(c1ccccc1C(O)=C1C(NCC(O)=O)=O)C1=O APYIJHRTLIKJFB-UHFFFAOYSA-N 0.000 description 1
- JCSCDPOJLDEXLM-AWEZNQCLSA-N CC(C)C[C@@H](C(O)=O)NC(C(C(N(c1ccccc11)OCC2CC2)=O)=C1O)=O Chemical compound CC(C)C[C@@H](C(O)=O)NC(C(C(N(c1ccccc11)OCC2CC2)=O)=C1O)=O JCSCDPOJLDEXLM-AWEZNQCLSA-N 0.000 description 1
- LAKDWDBVTNMSQP-UHFFFAOYSA-N CCC(CC)ON(c1ccccc1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CCC(CC)ON(c1ccccc1C(O)=C1C(NCC(O)=O)=O)C1=O LAKDWDBVTNMSQP-UHFFFAOYSA-N 0.000 description 1
- BVKQKPBOWMDWHU-UHFFFAOYSA-N COC(CNC(C(C(N(c1ccccc11)OCC2CC2)=O)=C1O)=O)=O Chemical compound COC(CNC(C(C(N(c1ccccc11)OCC2CC2)=O)=C1O)=O)=O BVKQKPBOWMDWHU-UHFFFAOYSA-N 0.000 description 1
- OLMKVNAYDVXHGU-UHFFFAOYSA-N CON(C(CSC1)=C1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CON(C(CSC1)=C1C(O)=C1C(NCC(O)=O)=O)C1=O OLMKVNAYDVXHGU-UHFFFAOYSA-N 0.000 description 1
- CAHHKQQPPLTDBH-UHFFFAOYSA-N COc(cc1)ccc1-c(cc1C(O)=C(C(NCC(O)=O)=O)C2=O)ccc1N2OCc1ccccc1 Chemical compound COc(cc1)ccc1-c(cc1C(O)=C(C(NCC(O)=O)=O)C2=O)ccc1N2OCc1ccccc1 CAHHKQQPPLTDBH-UHFFFAOYSA-N 0.000 description 1
- VNWXYKMVBRZDJD-UHFFFAOYSA-N CSCCON(c1ccccc1C(O)=C1C(NCC(O)=O)=O)C1=O Chemical compound CSCCON(c1ccccc1C(O)=C1C(NCC(O)=O)=O)C1=O VNWXYKMVBRZDJD-UHFFFAOYSA-N 0.000 description 1
- BVEZZPZBUWMUPP-UHFFFAOYSA-N OC(CNC(C(C(N(c1c2cccn1)Oc1ccc(C(F)(F)F)cc1)=O)=C2O)=O)=O Chemical compound OC(CNC(C(C(N(c1c2cccn1)Oc1ccc(C(F)(F)F)cc1)=O)=C2O)=O)=O BVEZZPZBUWMUPP-UHFFFAOYSA-N 0.000 description 1
- UAEPJZYMNCCRPK-HWKANZROSA-N OC(CNC(C(C(N(c1ccccc11)OCC/C=C/C2CC2)=O)=C1O)=O)=O Chemical compound OC(CNC(C(C(N(c1ccccc11)OCC/C=C/C2CC2)=O)=C1O)=O)=O UAEPJZYMNCCRPK-HWKANZROSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3600MU2012 | 2012-12-24 | ||
| IN3600/MUM/2012 | 2012-12-24 | ||
| PCT/IN2013/000796 WO2014102818A1 (en) | 2012-12-24 | 2013-12-23 | Novel quinolone derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150085535A KR20150085535A (ko) | 2015-07-23 |
| KR101733901B1 true KR101733901B1 (ko) | 2017-05-08 |
Family
ID=54148255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157016080A Active KR101733901B1 (ko) | 2012-12-24 | 2013-12-23 | 신규한 퀴놀론 유도체 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9394300B2 (https=) |
| EP (1) | EP2935221B1 (https=) |
| JP (1) | JP6026013B2 (https=) |
| KR (1) | KR101733901B1 (https=) |
| CN (1) | CN104903295B (https=) |
| AP (1) | AP2015008502A0 (https=) |
| AR (1) | AR094300A1 (https=) |
| AU (1) | AU2013368843B2 (https=) |
| BR (1) | BR112015014222B1 (https=) |
| CA (1) | CA2894636C (https=) |
| CL (1) | CL2015001802A1 (https=) |
| EA (1) | EA028402B1 (https=) |
| ES (1) | ES2660288T3 (https=) |
| IL (1) | IL239109B (https=) |
| JO (1) | JO3781B1 (https=) |
| MA (1) | MA38138A1 (https=) |
| MX (1) | MX373392B (https=) |
| MY (1) | MY175854A (https=) |
| NZ (1) | NZ708605A (https=) |
| PH (1) | PH12015501452B1 (https=) |
| SG (1) | SG11201504458XA (https=) |
| TR (1) | TR201802305T4 (https=) |
| TW (1) | TWI598339B (https=) |
| UA (1) | UA117122C2 (https=) |
| WO (1) | WO2014102818A1 (https=) |
| ZA (1) | ZA201503814B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016034108A1 (zh) * | 2014-09-02 | 2016-03-10 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其应用 |
| WO2016045125A1 (en) * | 2014-09-28 | 2016-03-31 | Merck Sharp & Dohme Corp. | Inhibitors of hif prolyl hydroxylase |
| CL2015003047A1 (es) * | 2015-10-15 | 2016-06-17 | Univ Chile | Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CN108069957B (zh) * | 2016-11-09 | 2022-11-04 | 广东东阳光药业有限公司 | 脯氨酰羟化酶抑制剂及其用途 |
| CA3062972C (en) * | 2017-05-09 | 2021-09-14 | Kind Pharmaceutical | Indolizine derivatives and their application in medicine |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| WO2021181360A1 (en) * | 2020-03-13 | 2021-09-16 | Cadila Healthcare Limited | Novel salts of quinolone compounds |
| US20230190731A1 (en) * | 2020-03-17 | 2023-06-22 | Zydus Lifesciences Limited | Formulation comprising hif prolyl hydroxylase inhibitors |
| WO2021216530A1 (en) | 2020-04-20 | 2021-10-28 | Akebia Therapeutics, Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| CN115666539A (zh) * | 2020-05-29 | 2023-01-31 | 兹杜斯生命科学有限公司 | 银屑病和皮肤炎性疾病的治疗 |
| EP4157220A1 (en) * | 2020-06-01 | 2023-04-05 | Zydus Lifesciences Limited | Treatment for the inflammatory bowel disease |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| EP4308120A4 (en) | 2021-03-19 | 2024-11-27 | Zydus Lifesciences Limited | TREATMENT OF SICKLE CELL ANEMIA |
| WO2022195525A1 (en) * | 2021-03-19 | 2022-09-22 | Zydus Lifesciences Limited | A quinolone compound in solid forms and processes for the preparation thereof |
| WO2022238745A1 (en) * | 2021-05-14 | 2022-11-17 | Zydus Lifesciences Limited | Topical pharmaceutical composition of hif prolyl hydroxylase inhibitors |
| EP4347022A1 (en) | 2021-05-27 | 2024-04-10 | Keryx Biopharmaceuticals, Inc. | Pediatric formulations of ferric citrate |
| CN113549011B (zh) * | 2021-08-10 | 2023-05-09 | 广东东阳光药业有限公司 | 德度司他的共晶或盐及其制备方法和用途 |
| CN117836275A (zh) * | 2021-09-20 | 2024-04-05 | 载度思生命科学有限公司 | 德度司他颗粒及其组合物 |
| EP4539934A1 (en) * | 2022-06-24 | 2025-04-23 | Zydus Lifesciences Limited | Treatment for glomerular diseases |
| EP4565233A1 (en) * | 2022-08-01 | 2025-06-11 | Zydus Lifesciences Limited | Treatment for aplastic anemia (aa) |
| WO2025087207A1 (zh) | 2023-10-24 | 2025-05-01 | 杭州安道药业有限公司 | 含有缺氧诱导因子-脯酰胺羟基化酶抑制剂的长效口服药物及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| WO2007103905A2 (en) * | 2006-03-07 | 2007-09-13 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ270267A (en) | 1993-12-30 | 1997-03-24 | Hoechst Ag | 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions |
| WO2004108681A1 (en) | 2003-06-06 | 2004-12-16 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin |
| US8703795B2 (en) * | 2005-03-02 | 2014-04-22 | Fibrogen, Inc. | Thienopyridine compounds, and methods of use thereof |
| EP1960363B1 (en) * | 2005-12-09 | 2014-01-22 | Amgen, Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions and uses thereof |
| BRPI0710527B8 (pt) * | 2006-04-04 | 2021-05-25 | Fibrogen Inc | compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende |
| US20090176825A1 (en) * | 2006-05-16 | 2009-07-09 | Fitch Duke M | Prolyl hydroxylase inhibitors |
| US20100056516A1 (en) * | 2006-07-17 | 2010-03-04 | Williams Peter D | 1-hydroxy naphthyridine compounds as anti-hiv agents |
| ES2393326T3 (es) * | 2006-12-18 | 2012-12-20 | Amgen, Inc | Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos |
| US8048894B2 (en) * | 2007-04-18 | 2011-11-01 | Amgen Inc. | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
| JP2010524935A (ja) * | 2007-04-18 | 2010-07-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 新規１，８−ナフチリジン化合物 |
| EP2155746A2 (en) * | 2007-05-04 | 2010-02-24 | Amgen, Inc | Diazaquinolones that inhibit prolyl hydroxylase activity |
| US8030346B2 (en) * | 2007-05-04 | 2011-10-04 | Amgen Inc. | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity |
| AU2008251031B2 (en) * | 2007-05-16 | 2013-12-19 | Norman Terry Cowper | System and method for maximising solids concentration of slurry pumped through a pipeline |
| JP2011505367A (ja) * | 2007-11-30 | 2011-02-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| AU2009217541A1 (en) * | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Tetrahydrothieno pyridines |
| CA2716798A1 (en) * | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Tetrahydrofuropyridones |
| CA2714111A1 (en) * | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Tetrahydro-1h-pyrrolo fused pyridones |
| US20110098324A1 (en) * | 2008-06-25 | 2011-04-28 | Brackley Iii James A | Prolyl hydroxylase inhibitors |
| EP3594213A1 (en) | 2009-07-17 | 2020-01-15 | Japan Tobacco Inc. | Triazolopyridine compounds and action thereof as prolyl hydroxylase inhibitors and erythropoietin production inducers |
| US20120196853A1 (en) * | 2009-08-20 | 2012-08-02 | Vifor (International) Ag | Novel Quinoline-Hepcidine Antagonists |
| WO2012106472A1 (en) | 2011-02-02 | 2012-08-09 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase |
| EP2758058B1 (en) | 2011-09-23 | 2017-04-26 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| CA2863279A1 (en) * | 2012-01-31 | 2013-08-08 | Toyama Chemical Co., Ltd. | Heterocyclic compound having anti-hiv activity |
-
2013
- 2013-12-23 JO JOP/2013/0383A patent/JO3781B1/ar active
- 2013-12-23 MX MX2015008233A patent/MX373392B/es active IP Right Grant
- 2013-12-23 WO PCT/IN2013/000796 patent/WO2014102818A1/en not_active Ceased
- 2013-12-23 AP AP2015008502A patent/AP2015008502A0/xx unknown
- 2013-12-23 KR KR1020157016080A patent/KR101733901B1/ko active Active
- 2013-12-23 NZ NZ708605A patent/NZ708605A/en unknown
- 2013-12-23 TR TR2018/02305T patent/TR201802305T4/tr unknown
- 2013-12-23 TW TW102147766A patent/TWI598339B/zh active
- 2013-12-23 CN CN201380067856.4A patent/CN104903295B/zh active Active
- 2013-12-23 ES ES13828997.0T patent/ES2660288T3/es active Active
- 2013-12-23 EA EA201591195A patent/EA028402B1/ru not_active IP Right Cessation
- 2013-12-23 CA CA2894636A patent/CA2894636C/en active Active
- 2013-12-23 MY MYPI2015001457A patent/MY175854A/en unknown
- 2013-12-23 BR BR112015014222-2A patent/BR112015014222B1/pt active IP Right Grant
- 2013-12-23 US US14/652,024 patent/US9394300B2/en active Active
- 2013-12-23 EP EP13828997.0A patent/EP2935221B1/en active Active
- 2013-12-23 UA UAA201506784A patent/UA117122C2/uk unknown
- 2013-12-23 SG SG11201504458XA patent/SG11201504458XA/en unknown
- 2013-12-23 AU AU2013368843A patent/AU2013368843B2/en active Active
- 2013-12-23 JP JP2015548889A patent/JP6026013B2/ja active Active
- 2013-12-27 AR ARP130105055A patent/AR094300A1/es active IP Right Grant
-
2015
- 2015-05-27 ZA ZA2015/03814A patent/ZA201503814B/en unknown
- 2015-05-29 MA MA38138A patent/MA38138A1/fr unknown
- 2015-06-01 IL IL239109A patent/IL239109B/en active IP Right Grant
- 2015-06-22 CL CL2015001802A patent/CL2015001802A1/es unknown
- 2015-06-23 PH PH12015501452A patent/PH12015501452B1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| WO2007103905A2 (en) * | 2006-03-07 | 2007-09-13 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101733901B1 (ko) | 신규한 퀴놀론 유도체 | |
| JP2022126843A (ja) | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 | |
| JP6867417B2 (ja) | キナーゼ阻害剤としてのｎ−（置換フェニル）−スルホンアミド誘導体 | |
| JP7511557B2 (ja) | ブロモドメインタンパク質阻害薬としてのイミノスルホン化合物、医薬組成物及びその医薬用途 | |
| JP2020527588A (ja) | アデノシンアンタゴニストとしてのヘテロ環式化合物 | |
| KR20100108337A (ko) | 사람 면역결핍 바이러스 복제의 억제제 | |
| EP2257169A1 (en) | Tetrahydrothieno pyridines | |
| KR19990071520A (ko) | 피리도[2,3-d]피리미딘 유도체 및 이의 의약 조성물 | |
| TWI748194B (zh) | 含有雙環核心部分之新穎lxr調節劑 | |
| WO2020241853A1 (ja) | ベンゾトリアゾール誘導体 | |
| CN112898284A (zh) | 一类抑制rna解旋酶dhx33的化合物及其应用 | |
| EP4089089A1 (en) | Polycyclic compounds for inhibiting rna helicase dhx33 and use thereof | |
| TW201639843A (zh) | Ｋｖ１．３抑制劑及其醫學應用 | |
| TWI683808B (zh) | 含有胺或(硫)醯胺之lxr調節劑 | |
| CN120379999A (zh) | 新型irak4抑制剂以及抑制并降解irak4蛋白的化合物及其制备方法和应用 | |
| HK1211022B (en) | Quinolone derivatives | |
| OA17332A (en) | Novel quinolone derivatives. | |
| TW201639857A (zh) | Ｋｖ１．３抑制劑及其醫學應用 | |
| KR102954013B1 (ko) | 브로모도메인 단백질 억제제로서의 설폭시민 화합물과 약학적 조성물 및 이의 의학적 용도 | |
| TW202529740A (zh) | Ｐｈｄ抑制劑化合物、組成物及使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 20150617 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| A302 | Request for accelerated examination | ||
| PA0302 | Request for accelerated examination |
Patent event date: 20160502 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20160817 Patent event code: PE09021S01D |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20161212 Patent event code: PE09021S02D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20170417 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20170428 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20170428 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20200416 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200416 Start annual number: 4 End annual number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20210415 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210415 Start annual number: 5 End annual number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20220415 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220415 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230420 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240418 Start annual number: 8 End annual number: 8 |